- Home
- Products
- Services
- Resources
- About Us
- News
- Contact
Views: 0 Author: Site Editor Publish Time: 2026-07-21 Origin: Site
HLA genotyping assays must deliver accurate, reproducible, and clearly interpretable results across different samples, reagent lots, operators, instruments, and laboratories. This requirement is especially important because HLA genes are highly polymorphic, and even a small difference in amplification, sequencing, allele assignment, or result interpretation may affect the final genotype call.
For this reason, laboratories and assay developers need well-characterized materials with known HLA genotypes. HLA reference standards provide defined test materials that can be used during assay development, analytical validation, method comparison, operator training, and routine quality control.
Unlike an unknown clinical sample, a reference standard has an assigned or confirmed genotype that can be compared with the result produced by the assay. This makes it possible to identify whether an unexpected result is related to assay design, reagent performance, sample processing, sequencing quality, data analysis, or operator handling.
This practical guide explains how HLA reference standards support assay validation and quality control, what characteristics should be evaluated before purchase, and how laboratories can incorporate them into a controlled testing workflow.
HLA reference standards provide samples with known and characterized genotypes for performance evaluation.
They support accuracy, precision, reproducibility, robustness, and result interpretation during assay validation.
Routine quality control can help identify reagent failure, contamination, instrument problems, and operational errors.
The selected material should match the assay’s target loci, typing resolution, sample format, workflow, and intended use.
Reference standards should complement, rather than replace, other controls such as no-template controls and extraction controls.
HLA reference standards are characterized biological or DNA-based materials containing defined HLA genotypes. They are used as test samples in HLA typing workflows to evaluate whether a method can correctly detect and assign the expected alleles.
Depending on the product design, an HLA standard may be provided for a single locus or for multiple HLA loci. It may also be designed for a specific typing resolution or detection workflow. The most important feature is that the expected genotype has been established through an appropriate characterization process and is supplied with sufficient technical documentation.
A reference standard normally includes information such as:
Target HLA locus or loci
Assigned allele designation
Typing resolution
Material format and concentration
Recommended storage conditions
Intended application
Characterization or sequencing method
Instructions for use and result interpretation
The purpose of the material is not to imitate every feature of a patient sample. Instead, it provides a reliable and traceable target against which the performance of an HLA assay can be assessed.
For laboratories developing or evaluating HLA typing workflows, the HLA Standard portfolio provides a starting point for reviewing available single-locus and multi-locus materials.
Assay validation demonstrates that a method is suitable for its intended use. In HLA genotyping, this involves more than confirming that amplification or sequencing has occurred. The assay must correctly identify the intended allele or allele combination and produce consistent results under defined conditions.
A well-characterized reference standard helps convert the validation process from a general technical assessment into an evidence-based evaluation.
Validation Activity | Role of an HLA Reference Standard | Typical Evidence Generated |
|---|---|---|
Accuracy assessment | Compares the reported genotype with the assigned genotype | Correct allele calls and agreement rate |
Repeatability testing | Tests the same material under the same conditions | Consistency within a run |
Reproducibility testing | Tests across operators, days, instruments, or reagent lots | Stability of results under changing conditions |
Workflow robustness | Evaluates performance under controlled variations | Identification of sensitive process steps |
Method comparison | Provides a common sample for different workflows | Agreement between methods or platforms |
Operator training | Offers a known result for interpretation practice | Assessment of technical competency |
The primary role of a reference standard is to determine whether the assay produces the correct result. The assigned genotype serves as the comparison point for the result generated by PCR, sequencing, hybridization, or another HLA typing workflow.
If the reported result differs from the expected genotype, the laboratory can investigate the cause. Possible factors may include insufficient DNA quality, ineffective amplification, allele dropout, nonspecific amplification, sequencing coverage gaps, incorrect software settings, or result interpretation errors.
A reference standard does not automatically prove that an assay is accurate for every HLA allele. However, it provides direct evidence for the alleles and loci represented by the material and can be included as part of a broader validation panel.
Repeatability refers to the consistency of results when the same material is tested under the same operating conditions. For example, a laboratory may test an HLA reference standard multiple times in one run or across several runs using the same instrument and reagent lot.
Reproducibility evaluates whether the same expected result can be obtained when selected conditions change. These conditions may include:
Different operators
Different testing days
Different reagent lots
Different instruments
Different laboratories
Different library preparation or analysis batches
Consistent performance across these conditions supports confidence in the stability of the assay workflow. If results vary, the reference standard helps the laboratory identify which part of the process requires further optimization or control.
HLA assays may include several stages, including DNA extraction, target amplification, library preparation, sequencing, data analysis, and final reporting. Each stage can affect the accuracy of the genotype call.
During robustness studies, a known reference material can be tested under carefully defined variations, such as different DNA input levels or changes within the permitted operating range. The goal is not to deliberately invalidate the method, but to determine whether normal process variation affects the result.
This information can help laboratories establish:
Acceptable DNA input ranges
Critical amplification conditions
Minimum sequencing or coverage requirements
Appropriate data quality thresholds
Conditions requiring repeat testing
Assay validation is performed before routine use, but quality control must continue after the method has been established. A validated assay can still produce unreliable results if a reagent deteriorates, an instrument performs incorrectly, contamination occurs, or an operational error affects the workflow.
A known HLA standard can be included at a defined frequency based on the laboratory’s quality system and testing volume. The frequency should be determined by the intended use, assay design, applicable requirements, and documented risk assessment.
A reference standard may be used to determine whether a testing run meets predefined acceptance criteria. The expected genotype should be reported correctly, and the associated quality metrics should meet the laboratory’s established requirements.
If the control result is inconsistent with the assigned value, the laboratory should avoid releasing affected results until the deviation has been assessed. Depending on the investigation, the affected batch may need to be repeated.
Control results can be trended over time to identify gradual changes in assay performance. A sudden change after a new reagent lot, primer set, sequencing kit, or analysis software update may indicate a lot-related or workflow-related issue.
Using the same characterized material across different lots can make comparison easier. However, laboratories should document changes in material lots and confirm that the new lot is suitable before replacing the previous control material.
When a reference standard produces an unexpected result, it provides an early warning that the process may not be operating as intended. Investigation may include:
Checking sample identification and handling records
Reviewing DNA concentration and quality
Examining amplification or library preparation data
Reviewing sequencing coverage and quality metrics
Confirming software and database settings
Repeating the test using the same or an independent control
Comparing results with previous runs
The control does not identify the root cause by itself, but it helps narrow the investigation and separates assay-related problems from unusual clinical sample characteristics.
HLA result interpretation can be technically demanding, particularly when the assay produces ambiguous or high-resolution results. A characterized reference standard can be used during onboarding, competency assessment, and refresher training.
New operators can process the material using the established workflow and compare the result with the expected genotype. This provides a practical way to assess both laboratory operation and interpretation skills.
The correct material should be selected according to the assay’s intended use rather than by product name alone.
First, identify which HLA loci the assay is designed to test. Some workflows focus on one locus, while others examine multiple loci in the same sample. The reference standard should contain the relevant target region or regions.
CB-Gene provides single-locus HLA controls as well as multi-locus HLA matching controls. The detailed selection between these formats should depend on the assay design and validation plan.
The standard should be suitable for the resolution reported by the assay. A material intended for a lower-resolution workflow may not be sufficient for an assay that reports more detailed allele information.
The assigned allele designation, reporting format, and expected resolution should be reviewed before testing begins. The laboratory should also define how ambiguous or partially resolved results will be handled.
The format of the standard should be compatible with the intended workflow. Whole-genome DNA may be suitable for laboratories that begin validation after DNA extraction, while a cellular format may be more appropriate when the laboratory needs to evaluate sample processing and extraction steps.
A human cell background can provide a testing context that more closely reflects certain clinical sample workflows. However, the material format should still be evaluated against the laboratory’s own extraction method, input requirements, and stability conditions.
The assigned genotype should be supported by an appropriate characterization method. Depending on the material, characterization may involve Sanger sequencing, PCR-SBT, third-generation sequencing, or sequence alignment against a recognized HLA allele database.
The documentation should clearly identify which regions were examined and how the genotype was confirmed. This is particularly important when the standard will be used for assay validation or when the results will support technical or regulatory documentation.
A reference standard may be used over an extended validation or quality control period. Stable supply and controlled batch-to-batch consistency can reduce the risk of changing the control material during a study.
When reviewing a supplier, laboratories should consider:
Availability of technical documentation
Lot information and certificates
Storage and shipping conditions
Recommended handling procedures
Replacement lot availability
Technical support for application questions
A simple implementation process can help laboratories use HLA standards consistently.
Clarify whether the material will be used for assay development, analytical validation, method comparison, operator training, routine QC, or troubleshooting.
Document the target loci, typing resolution, sample format, DNA input range, testing platform, and reporting requirements.
Test the reference standard under normal operating conditions and confirm that the result agrees with the assigned genotype. Record all relevant quality metrics.
Use the material in accuracy, repeatability, reproducibility, and robustness studies according to the validation plan. Acceptance criteria should be defined before the results are reviewed.
Specify when the material will be tested, what result is acceptable, who will review deviations, and when a run must be repeated or investigated.
Maintain records of control results, quality metrics, reagent lots, operators, instruments, and deviations. Long-term trending can reveal changes that may not be obvious in a single run.
One reference standard cannot represent all possible HLA alleles, loci, resolutions, or sample conditions. A broader validation design may require multiple materials with different genotypes.
An HLA reference standard can confirm performance for a known genotype, but it does not replace every other control. No-template controls, extraction controls, internal controls, and other process controls may still be necessary.
A DNA-only material may not evaluate the extraction step, while a cellular material may introduce handling requirements that are not relevant to a specific workflow. The format should match the part of the process being validated.
Changing the control material during a long validation study can make results more difficult to compare. Any replacement lot should be reviewed, documented, and evaluated according to the laboratory’s procedures.
The laboratory should establish what constitutes an acceptable genotype result and which quality metrics must be met before testing begins. Reviewing results without predefined criteria may lead to inconsistent decisions.
HLA reference standards are practical tools for establishing confidence in HLA genotyping assays. They provide known and characterized materials that can be used to assess accuracy, repeatability, reproducibility, robustness, and result interpretation.
Their value continues after validation. When incorporated into routine quality control, HLA standards can help laboratories monitor reagent and instrument performance, identify workflow deviations, support operator training, and improve the reliability of reported results.
The most suitable standard depends on the assay’s target loci, typing resolution, material format, characterization requirements, and intended use. By selecting an appropriate material and integrating it into a documented validation and QC plan, laboratories can build a more consistent and traceable HLA testing workflow.
For laboratories evaluating HLA reference materials for assay development or quality control, CB-Gene’s HLA reference standard products provide options for single-locus and multi-locus applications.
An HLA reference standard contains a known and characterized genotype. It is used to evaluate assay accuracy, repeatability, reproducibility, workflow performance, and result interpretation during validation and routine quality control.
Yes. It can be included in routine QC to monitor whether an HLA assay continues to produce the expected result. The testing frequency and acceptance criteria should be defined in the laboratory’s quality procedures.
No. One material may only represent selected loci, alleles, resolutions, or sample formats. Additional materials may be needed to evaluate different parts of the assay or different intended-use conditions.
Laboratories should review the assigned genotype, target loci, typing resolution, material format, characterization method, sequence coverage, storage conditions, and certificate or technical documentation.
No. A reference standard generally provides a known target for performance evaluation. It should not automatically replace no-template controls, extraction controls, internal controls, or other controls required by the assay design.
